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SUMMARY 
Quinone-based compounds have been exploited to treat infectious diseases and cancer, 
with such chemicals often functioning as inhibitors of key metabolic pathways or as 
prodrugs. Here, we screened an aziridinyl-1,4-benzoquinone (ABQ) library against the 
causative agents of trypanosomiasis, and cutaneous leishmaniasis, identifying several potent 
structures that exhibited EC50 values of <100 nM. However, these compounds also displayed 
significant toxicity towards mammalian cells indicating that they are not suitable therapies for 
systemic infections. Using anti-T. brucei ABQs as chemical probes, we demonstrated that 
these exhibit different trypanocidal modes of action. Many functioned as type I nitroreductase 
(TbNTR) or cytochrome P450 reductase (TbCPR) dependent prodrugs that, following 
activation, generate metabolites which promote DNA damage, specifically interstrand 
crosslinks (ICLs). Trypanosomes lacking TbSNM1, a nuclease that specifically repairs ICLs, 
are hypersensitive to most ABQ prodrugs, a phenotype exacerbated in cells also engineered 
to express elevated levels of TbNTR or TbCPR. In contrast, ABQs that contain substituent 
groups on the biologically active aziridine do not function as TbNTR or TbCPR-activated 
prodrugs and do not promote DNA damage. By unravelling how ABQs mediate their 
activities, features that facilitate the desired anti-parasitic growth inhibitory effects could be 
incorporated into new, safer compounds targeting these neglected tropical diseases.  
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INTRODUCTION 
The protozoan parasites Trypanosoma brucei, T. cruzi and various Leishmania species are the 
etiological agents of human African trypanosomiasis (HAT), Chagas disease and 
Leishmaniasis, respectively. Spread by the hematophagous habits of insect vectors, these 
pathogens cause more than 55,000 deaths per year and are prevalent in many regions of the 
world least able to deal with the associated economic burden (http://www.dndi.org/diseases-
projects/). Implementation of new surveillance and treatment programmes in conjunction 
with improved housing and vector control strategies has resulted in a dramatic reduction in 
disease prevalence. For example, the number of new cases of HAT has fallen from an 
estimated peak of 450,000 in 1997 to below 20,000 in 2014 while Chagas disease has been 
eliminated from Chile, Uruguay and several regions of Argentina and Brazil (Barrett, 2006, 
Schofield et al., 2006, WHO, 2014). The success of such strategies has led to the World 
Health Organisation (WHO) aiming to eliminate HAT as a public health problem by 2020 
(WHO, 2013). 
Currently, drugs represent the only viable option to combat trypanosomal and leishmanial 
infections although their use is problematic. They often require supervision for 
administration, can be costly, have limited efficacy and may cause significant toxicity. 
Additionally, drug resistance is beginning to further limit the efficacy of the available 
chemotherapeutic arsenal, with antimonials no longer recommended as a first line treatment 
for leishmaniasis on the Indian sub-continent due to widespread resistance (Wilkinson & 
Kelly, 2009, Barrett & Croft, 2012, Alsford et al., 2013, Perry et al., 2015). In the case of 
HAT and Chagas disease, the front line treatments involve nitroheterocyclic-based prodrugs 
with nifurtimox or benznidazole monotherapies used to target T. cruzi while nifurtimox, in 
combination with difluoromethylornithine (DFMO), is employed against a form of HAT 
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prevalent throughout West and Central Africa (REF) (Priotto et al., 2009, Yun et al., 2010, 
Wilkinson et al., 2011). To mediate their trypanocidal effects, nifurtimox and benznidazole 
undergo an activation reaction catalysed by an FMN-containing, mitochondrial type I 
nitroreductase (NTR),  generating cytotoxic reduction products (Wilkinson et al., 2008, Hall 
et al., 2011, Hall & Wilkinson, 2012). For nifurtimox this results in the production of an 
unsaturated open chain nitrile while benznidazole is processed to glyoxal via a series of 
highly reactive intermediates. As type I NTRs are expressed by some unicellular eukaryotes 
(including trypanosomes and Leishmania) but not by metazoan organisms, the bioreductive 
activity of this enzyme has been exploited to develop a series of novel antiparasitic 
nitroaromatic- and benzoquinone-based prodrugs (Wilkinson et al., 2011, Patterson & 
Wyllie, 2014). Several of these display significant potency against T. brucei in vitro while 
exhibiting little or no toxicity towards cultured mammalian cells. 
Quinones represent a class of organic compounds that contain two carbonyl groups 
attached to a six membered carbocyclic backbone. They are ubiquitous in nature, functioning 
in various oxidoreductase cascades, with some natural and synthetic variants being of 
pharmacological interest. In the latter case, many quinone-based agents often function as 
prodrugs and must undergo activation before they can mediate their cytotoxic effects, 
reactions catalysed by quinone oxidoreductases (McKeown et al., 2007, Siegel et al., 2012). 
Based on oxygen-sensitivity, such enzymes can be divided into two groups. Oxygen-sensitive 
quinone oxidoreductases, such as NADH cytochrome b5 reductase and cytochrome P450 
reductase (CPR), can mediate the 1e- reduction of one of the quinone’s carbonyl oxygens to 
form an unstable semiquinone radical that, under hypoxic conditions, can be further reduced 
to the hydroquinone derivative (Powis, 1989, O'Brien, 1991). However, in the presence of 
oxygen, the semiquinone radical can undergo futile cycling, generating superoxide anions 
and regeneration of the parent compound. In contrast, oxygen-insensitive quinone 
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oxidoreductases, such as NAD(P)H quinone oxidoreductase 1 (NQO1), catalyse the 
simultaneous 1e- reduction of both the quinone’s carbonyl oxygens to form the hydroquinone 
directly (Ernster et al., 1962, Iyanagi & Yamazaki, 1970, Siegel et al., 2012). Dependent on 
structural context, this conversion can result in stable pharmacologically active products, as is 
the case for the benzoquinone ansamycin antibiotics, or unstable metabolites that undergo 
further rearrangement before exerting their toxic effects, as seen with the antitumor agents 
mitomycin A and β-lapachone (Siegel et al., 2012). 
Due to their favourable redox and electrochemical properties, compounds containing a 
quinone pharmacophore represent attractive scaffolds for antimicrobial drug development 
(Pinto & de Castro, 2009, Beena & Rawat, 2013).  Screening against trypanosomes has 
resulted in the identification of various natural and synthetic lead structures postulated to 
function as prodrugs promoting oxidative stress within the parasite or through formation of 
toxic bioreductive products (Henderson et al., 1988, Kubata et al., 2002, Hoet et al., 2004, 
Pinto & de Castro, 2009, Ramos et al., 2009, Garavaglia et al., 2010, Hall et al., 2012). Using 
recombinant T. brucei that lack TbSNM1, a DNA repair enzyme that specifically fixes 
interstrand crosslinks (ICLs) (Sullivan et al., 2015), while expressing elevated levels of 
oxygen-sensitive (TbCPR) or –insensitive (TbNTR) quinone oxidroreductases, we 
demonstrate that many aziridinyl 1,4-benzoquinones (ABQs) possess significant potency 
towards trypanosomatid parasites, with different structures undergoing distinct activation 
mechanisms to generate metabolites that subsequently promote DNA damage within the 
parasite nucleus. 
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RESULTS 
Antiparasitic activity of aziridinyl benzoquinones. 
Compounds containing an aziridinyl 1,4-benzoquinone (ABQ) core display potent 
anticancer properties particularly against cells where NADPH quinone oxidoreductase 1 
(NQO1) expression is up-regulated (Lin et al., 1972, Lusthof et al., 1989, Dehn et al., 2004). 
Recently, the antiparasitic activities of such compounds towards Plasmodium falciparum and 
T. brucei has been investigated with several potential lead structures identified (Grellier et al., 
2010, Hall et al., 2012). Here, we have expanded on these initial trypanosomal screens to 
evaluate the growth inhibitory properties of a larger ABQ library against T. brucei, T. cruzi 
and L. major (Table 1). Out of the 34 compounds tested, 20, 14 and 16 had no effect on T. 
brucei, T. cruzi and L. major growth, respectively, at concentrations of up to 10 µM. These 
were not analysed further. For the remaining compounds, RH1 exhibited potencies, expressed 
as the compound concentration that inhibits cell growth by 50% (EC50), of <100 nM towards 
bloodstream form T. brucei, with a further five (DZQ, ABQ3, ABQ6, TZQ and ABQ22) 
exhibiting moderate potency towards this parasite (EC50 values of 100-500 nM). Against T. 
cruzi epimastigotes, DZQ, TZQ and RH1 were highly active, yielding EC50 values <10 nM, 
with others displaying high (EC50 values between 10 and 100 nM; MeDZQ, ABQ22 and 
ABQ24) or moderate (EC50 values between 100 and 500 nM; ABQ4, ABQ6 and ABQ14) 
growth inhibitory effects. When tested against L. major promastigotes, TZQ exhibited an 
EC50 of <10 nM, with three other compounds (DZQ, RH1 and ABQ25) exhibiting high 
potency and eight others yielding moderate potency. Of all the ABQs analysed, RH1 was the 
most potent agent tested against all three parasites, yielding EC50 values of 19 ± 1, 3 ± 1 and 
68 ± 1 nM against T. brucei, T. cruzi and L. major, respectively. 
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Cytotoxicity against mammalian cells 
To evaluate whether those ABQs that displayed activity against the three trypanosomatid 
parasites exhibited toxicity to mammalian cells, their inhibitory properties against 
differentiated THP-1 cells was determined (Table 1). For 7 out of 8 structures tested, an in 
vitro toxicity was observed (EC50 values <10 µM), with two compounds, including RH1, 
being extremely toxic and yielding EC50 values of <100 nM. Comparison of the mammalian 
toxicity and antiparasitic EC50 data allowed a crude measure of each agent’s selectivity (the 
Selectivity Index or SI) toward the pathogen. In many cases, the ABQs displayed a higher 
potency against THP-1 cells relative to the parasite, resulting in a SI value <1. Of those that 
did display preferential activity against the parasite, the observed selective toxicity (<50) of 
most was equivalent to that seen with nifurtimox, an agent whose use in humans is 
problematic. The toxicity of these compounds towards cultured mammalian cells precluded 
any attempt to establish the potency of these structures against the intracellular amastigote 
forms of T. cruzi and L. major. 
As THP-1 cells are an immortal human monocyte line and ABQs have potent activity 
against cancerous cells (Tan et al., 1984, Lee et al., 1986, Moore et al., 1997), a series of 
screens using a selected quinone series on non-cancerous mouse peritoneal macrophages 
were performed. For DZQ, RH1, TZQ and ABQ22, substantial toxicity towards this line was 
observed with the compounds generating EC50 values of 255, <100, <100 and 120 nM, 
respectively. This clearly demonstrates that ABQs are toxic to primary cells, thus supporting 
our THP-1 findings. In light of the mammalian toxicity issues, our focus on ABQs switched 
from exploring them as potential treatments for infectious diseases to using them as tools to 
dissect trypanosomal pro-drug activation pathways and the structure-activity relationships 
among this class of compound. 
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Different trypanosomal mechanisms activate aziridinyl benzoquinone prodrugs. 
The application of genome-scale RNAi screens has helped elucidate the trypanocidal 
mechanism of action of a number of agents and identify how the affected pathways may 
impinge on drug resistance (Alsford et al., 2012, Alsford et al., 2013). As an initial step to 
understanding how ABQs mediate their antiparasitic activities, a loss-of-function screen was 
conducted on bloodstream form T. brucei, using RH1 as the selective agent (Fig 1A). 
Treatment of the parasite RNAi library with this compound resulted in reduced T. brucei 
growth over the first week followed by the outgrowth of an RH1-resistant population. 
Genomic DNA was extracted from the RH1-selected cells and RNAi targets were amplified, 
from which a single ~1.1 kbp fragment was identified as the major amplicon (Fig. 1B). 
Sequence analysis and comparison against the reference genome database revealed that this 
RH1-resistance-associated fragment mapped to a region encompassing the 5’ untranslated 
region and 5’ coding sequence of the open reading frame (Gene ID: Tb927.7.7230 on 
TriTrypDB - http://tritrypdb.org/tritrypdb/) for the type I nitroreductase, TbNTR (Fig. 1C). 
This was not unexpected given that this protein had been previously associated with the 
activation of trypanocidal nitroheterocyclic-based prodrugs, nifurtimox and benznidazole 
(Wilkinson et al., 2008, Hall et al., 2011, Hall & Wilkinson, 2012, Baker et al., 2011), and 
postulated to function as a NADH dependent quinone oxidoreductase (Wilkinson et al., 2008, 
Alsford et al., 2012, Hall et al., 2012).  
To conclusively show that TbNTR is the key activator of ABQs, we evaluated the 
susceptibility of a T. brucei Tbntr heterozygote line to RH1. These recombinant cells 
displayed an EC50 approximately 2.5-fold greater than that observed using wild type parasites 
(Fig. 2A) confirming that reduction of TbNTR expression through loss of one of the alleles 
encoding for this oxidoreductase is sufficient to generate resistance to RH1. As reduction of 
TbNTR activity leads to RH1 resistance, gain of function via over expression of the 
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oxidoreductase should have the converse effect, generating cells that are more susceptible to 
the ABQ. To determine if this was the case, the quinone-sensitivity of a T. brucei line 
engineered to express elevated levels of the enzyme was evaluated. In agreement with 
previous findings, parasites over expressing TbNTR were hypersensitive (approximately 4-
fold) to RH1 as compared to controls (Fig. 2B). 
To determine whether TbNTR plays a role in activating other ABQs, the susceptibility of 
TbNTR over expressing parasites towards a selected group of compounds, was tested (Table 
2). Out of the additional compounds screened, three (DZQ, MeDZQ and TZQ) showed the 
same hypersensitivity profile as RH1, with TbNTR over expressing T. brucei being up to 3.5-
fold more susceptible to the aziridinyl agents than controls. In contrast, ABQ22-24 and 30 did 
not follow this pattern, with the TbNTR over expressers exhibiting an EC50 equivalent to that 
observed against control cells.  
Dependent on backbone configuration, the carbonyl oxygen atoms in a quinone can 
undergo 1 or 2e- reduction, with the former reaction carried out by a range of ubiquitous 
flavoproteins, including cytochrome P450 reductase (CPR), while the latter is catalysed by 
enzymes, such as NQO1 and type I NTRs. To determine whether the trypanocidal activity 
displayed by selected ABQs can undergo activation via a 1e- reduction mechanism, the 
susceptibility of T. brucei lines engineered to express ectopic copies of the TbCPR2 or 3 
(Hall et al., 2011) to RH1, TZQ and ABQ22-24 was evaluated (Table 2). With RH1, TZQ, 
ABQ23 and ABQ24, the TbCPR over expressing lines exhibited EC50 values similar to those 
observed using control cells, indicating that the 1e- reduction pathway plays no significant 
role in their activation. When the T. brucei line expressing elevated levels of TbCPR2 or 3 
was tested against ABQ22, the recombinant lines were hypersensitive to this tetra-aziridinyl 
agent relative to controls (Fig. 2C). 
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Based on the above data, the trypanocidal activity of ABQs can be divided into 
compounds such as RH1 and TZQ that function as TbNTR-dependent (oxygen-insensitive 
quinone oxidoreductase) prodrugs, structures including ABQ22 that function as TbCPR-
dependent (oxygen-sensitive quinone oxidoreductase) prodrugs and agents such as ABQ23 
and 24 that are not activated by either of these two mechanisms: ABQ23 and 24 may still 
function as prodrugs undergoing activation by an alternative mechanism(s) to that explored 
here. 
  
Trypanosomes selected for resistance toward RH1 have reduced NTR expression. 
A further approach to determine how ABQs mediate their trypanocidal activity involved 
the selection of T. brucei lines resistant to RH1. Wild type bloodstream form parasites were 
grown in the presence of RH1 over a 100 day period, starting with a compound concentration 
that inhibits T. brucei growth by ~10% (5 nM) and progressively increasing this to twice the 
EC50 (40 nM) (Fig. 3A). The cumulative cell density of selected cultures were followed 
throughout the experiment. Of the three replica cultures analysed, two stopped growing when 
the selective pressure was increased to 20 nM. In contrast, cells in the third culture remained 
viable in 40 nM RH1 and parasites in this population were cloned by limiting dilution 
(designated as RH1RC). We then evaluated the growth properties of two RH1RC lines (RH1RC1 
and RH1RC2) (Fig. 3B). In the absence of RH1, the doubling time of the two clones was 
comparable to the parental line (doubling time of ~ 7.5 hours). When grown in medium 
containing RH1 (40 nM) the doubling time of the resistant clones increased ~1.5-fold 
(doubling time of ~ 10.5 hours); by comparison, no growth of wild type T. brucei was 
detected after 24 hrs. Next, we determined the susceptibility of the RH1RC lines towards RH1 
with this showing that both lines were ~3.5-fold less sensitive to the ABQ than wild type 
(Fig. 3C and D); wild type, RH1RC1 and RH1RC2 exhibited EC50 values of 25 ± 6, 83 ± 2 and 
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92 ± 1 nM against RH1, respectively. This resistance phenotype was not lost following 100 
generations in medium lacking RH1. Indeed, the resistant lines were still ~4.5-fold less 
sensitive to the ABQ than controls; wild type, RH1RC1 and RH1RC2 exhibited EC50 values of 
19 ± 1, 86 ± 3 and 91 ± 11 nM against RH1, respectively. When the above susceptibility 
studies were extended to TbNTR-activated prodrugs, cross-resistance towards nifurtimox, 
benznidazole, megazol, CB1954 and LH17 was observed (Table 3). This phenotype was 
specific to this class of compound, as the RH1 selected cells were equally sensite to the non 
TbNTR-activated compounds, including ABQ22 and other ICL inducing agents, as wild type 
T. brucei. 
Studies aimed at deciphering the RH1 resistance mechanism demonstrated that although 
the Tbntr copy number was similar and Tbntr gene sequences were identical in the compound 
selected and wild type lines, the RH1RC cells had a lower (~50%) Tbntr mRNA expression 
level (Fig. 4). Intriguingly, when extended to genes expressed in the same polycistron as 
Tbntr, all the tested ORFs exhibited the same trait in relation to copy number and transcript 
levels. The observed reduction in gene expression within the Tbntr-containing polycistron in 
the RH1 selected cells is specific to this region as additional ORFs present elsewhere in the T. 
brucei genome (for example Tb927.7.7490 and Tb927.7.6620, and the genes encoding for the 
DNA repair enzymes TbSNM1, TbMRE11, TbRAD51, TbXPG, TbEXO1, TbCSB and 
TbMSH3) are expressed at equivalent levels in RH1RC and control parasites. 
 
Aziridinyl benzoquinones promote cell cycle arrest and DNA damage in trypanosomes. 
Aziridinyl benzoquinones mediate their toxicity against mammalian cells through 
formation of ICLs that promote cell cycle arrest and DNA damage (Kim et al., 2004, Dehn et 
al., 2005, Begleiter et al., 2007).  To determine if this is the case in T. brucei, parasites at 
various stages in the cell cycle were identified in asynchronous cultures by staining their 
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nuclear (N) and mitochondrial (known as the kinetoplast (K)) genomes with DAPI; a non-
dividing trypanosome cell usually contains one mitochondrion and hence one kinetoplast. 
The ratio of these two DNA-containing structures represents an excellent marker for the 
trypanosomal cell cycle, with T. brucei in the G1/S phase having a 1N1K arrangement, those 
in G2/M phase possessing a 1N2K ratio while cells displaying a 2N2K profile are in the post-
M stage (Woodward & Gull, 1990, Siegel et al., 2008, Glover & Horn, 2012). For untreated 
T. brucei and cells exposed to phleomycin, most (approximately 80%) were in the G1/S stage 
of the cell cycle with a smaller percentage (12 to 20%) in G2/M (Fig. 5). In contrast, when 
trypanosomes were treated with RH1 or mechlorethamine (a well characterised ICL inducing 
agent), 58% and 45% of the cells displayed a configuration typical of the G2/M phase, 
respectively, with only 37% and 53% exhibiting a 1N1K DNA staining pattern, respectively. 
This indicates that treatment of T. brucei with RH1 (or mechlorethamine) results in a G2/M 
cell cycle arrest phenotype, potentially as a result of damaged DNA and is consistent with 
observations made with mammalian cells (Kim et al., 2004, Dehn et al., 2005). 
In most cells, ICLs are repaired through the concerted action of a number of 
complementary and overlapping pathways with enzymes belonging to the SNM1/PSO2 
family playing a specific role. In T. brucei, the enzyme TbSNM1, a member of the 
SNM1/PSO2 nuclease family, has been shown to play a specific and key role in repairing 
such damage (Sullivan et al., 2015). To evaluate whether deletion of both copies of Tbsnm1 
from the T. brucei genome altered the cells sensitivity to ABQs, the null mutant 
trypanosomes were grown in the presence of selected trypanocidal quinones and the EC50 
values for each compound determined (Table 4; Fig. 6). For all the ABQ prodrugs tested, 
cells lacking the nuclease were up to 6.6-fold more susceptible to these structures than 
control parasites. In contrast, assays using ABQ23 and ABQ24, the two ABQs that do not 
function as TbNTR- or TbCPR-activated prodrugs, and the trypanocidal agents nifurtimox 
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and difluoromethylornithine (DFMO), revealed no significant difference in the EC50 
exhibited by the engineered and control lines. 
To conclusively demonstrate that the above altered susceptibility phenotype was solely 
due to lack of TbSNM1 activity, the sensitivity of null mutant cells expressing an ectopic 
copy of Tbsnm1 towards DZQ, RH1 and ABQ22 was evaluated (Fig. 6). In all three cases, 
the TbSNM1-complemented line generated dose response curves and EC50 values distinct 
from those observed when using TbSNM1 null mutant cells but similar to those obtained 
using wild type parasites. 
 
Linking prodrug activation with DNA damage 
To establish whether there is a link between activation of the trypanocidal ABQs and the 
TbSNM1-mediated DNA repair pathway, the susceptibility of Tbsnm1 null-mutants 
expressing ectopic copies of Tbntr or Tbcpr2 towards selected compounds was evaluated 
(Fig. 7). When these lines were treated with RH1 or TZQ, an increased susceptibility was 
observed relative to wild type controls (Fig. 7A); Tbsnm1 null-mutants and T. brucei over 
expressing Tbntr were 3- and 5-fold more susceptible to RH1, respectively, and 2.7- and 3.4-
fold more susceptible to TZQ than wild type T. brucei. For Tbsnm1 null parasites expressing 
an ectopic copy of Tbntr, this increase in potency was magnified further, with these cells 
showing a 15-fold increase in susceptibility to both compounds as compared against wild 
type. Extending these studies to investigate the susceptibility of Tbsnm1 null-mutant parasites 
engineered to express an ectopic copy of Tbcpr2 towards ABQ22 yielded similar results (Fig. 
7B). When Tbsnm1 null mutants or wild type cells engineered to express an ectopic copy of 
Tbcpr2 were treated with ABQ22 a 7-fold increase in susceptibility was observed by both 
lines compared against controls. The growth inhibitory effect of this compound was further 
enhanced in trypanosomes that lack TbSNM1 activity while expressing elevated levels of 
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TbCPR2 (Fig. 7B), with these cells being 12.5-fold more sensitive to ABQ22 than wild type. 
The above alterations in susceptibilities were specific to the ABQs as all lines tested 
exhibited equivalent sensitivities to the non-DNA damaging trypanocidal agent DFMO. 
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DISCUSSION 
Interstrand crosslinks (ICLs) represent a highly toxic form of DNA damage that blocks 
processes dependent on DNA strand separation, such as replication and transcription. As 
rapidly dividing cells are particularly susceptible to this type of lesion, agents that are able to 
promote ICLs are of interest in the treatment of cancer and infectious diseases (Chen & Hu, 
2009, Deans & West, 2011, Wilkinson et al., 2011). Here, we report that several ABQs, ICL 
inducing chemicals originally developed as anti-cancer agents, can also function as highly 
potent anti-trypanosomatid prodrugs with different structures able to undergo activation via 
different pathways. In these cases, activation promotes a type of DNA damage that is repaired 
by a pathway where SNM1, a nuclease that only functions in ICL repair, plays a key role. 
Invariably, aziridine-containing compounds function as prodrugs with activation requiring 
protonation of the aziridinyl nitrogen. The ease with which this reaction can occur is 
governed by the compound’s chemical composition and how this influences the pKa of the 
aziridine. For certain structures (e.g. triethylenemelamine, thioTEPA and ‘simple’ ABQs 
including ABQ11) protonation can readily take place in aqueous solution due to the relatively 
high pKa of the aziridine within such backbones (Akhtar et al., 1975). However, for other 
agents, the pKa of the heterocycle is comparatively low, therefore preventing the above 
activation event. To circumnavigate this issue, the aziridine motif can be incorporated into a 
chemical backbone that also contains a bioreductive moiety, such as a quinone or 
nitroaromatic. Here, enzymatic reduction of carbonyl oxygen or nitro groups triggers a 
redistribution of electrons around the associated cyclical structure that can raise the pKa of 
the aziridinyl ring, and thus facilitating nitrogen protonation (Fig. 8A) (Hargreaves et al., 
2000). 
Using a combination of a whole genome loss-of-function screen, selection of resistant 
lines and/or functional genomic approaches, we have shown that T. brucei expresses at least 
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two ABQ bioreductive systems. For the eight compounds evaluated as potential prodrugs, 
half (DZQ, MeDZQ, RH1 and TZQ) were shown to be NTR activated, one (ABQ22) was 
shown to be dependent on a CPR activity, while the remainder (ABQ23, 24 and 30) were not 
reduced by any of the systems tested. For those that appeared not to function as prodrugs, this 
may be due to their structures, as these compounds contain methyl substituted aziridines (Fig. 
8B). These alkyl groups may block protonation and thus activation of the aziridinyl nitrogen 
by lowering this motif’s pKa and/or hinder access of oxidoreductases to the carbonyl groups 
(Lusthof et al., 1989, Phillips et al., 1999). These possibilities may also account for why 
other compounds that contain methyl/dimethyl aziridine substitutions (e.g. ABQs 25-30 and 
31-34) consistently displayed no or a lower activity against T. brucei than their non-
substituted counterparts, mirroring observations made in high throughput oncological screens 
(Kim et al., 2016). 
For those compounds that do function as trypanocidal prodrugs, the nature of the side 
chains found at the 3,6 positions on the benzoquinone ring appears to influence which 
activation mechanism predominates (Fig. 8B). For structures possessing small substituents at 
one or both sites, reduction occurs via a type I NTR activity with this mechanism unaffected 
by the presence of equivalent (e.g. hydrogen for DZQ, methyl for MeDZQ) or divergent (e.g. 
hydroxymethyl and methyl in RH1, aziridine and hydrogen in TZQ) groupings at the 3,6 
positions. Such small side chains may aid type I NTR/compound interaction or help the 
prodrug (or its activated products) gain access to the site(s) of action. In contrast, the 
presence of bulkier groups (e.g. aziridines for ABQ22) at both sites results in CPR activation. 
Why this mechanism operates to reduce this particular compound is open to speculation but it 
may reflect a steric hindrance effect such that the four aziridine groups found in ABQ22 
preclude TbNTR from interacting with and reducing its quinone carbonyl groups while 
facilitating associations with TbCPR isoforms. Alternatively, this difference could be due to 
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subcellular localisation such that ABQ22 may be readily transported into the T. brucei 
endoplasmic reticulum, the organelle where the TbCPRs are believed to reside, but unable to 
gain access to the parasite’s mitochondrion, the site where TbNTR is found (Wilkinson et al., 
2008). 
Following protonation of the aziridinyl nitrogen, the resultant electrophilic intermediate 
undergoes nucleophilic attack leading to opening of the heterocyclic ring, formation of an 
aliphatic amine then alkylation of the target (Fig. 8A) (Hargreaves et al., 2000). If the 
targeting compound contains multiple aziridinyl groups, as is the case for the ABQs tested 
here, and the nucleophile is DNA, then two nucleobases within the nucleic acid double helix 
become covalently crosslinked. In many eukaryotes the SNM1 (also known as PSO2) 
nuclease plays a key role in resolving such DNA damage, with cells lacking this activity 
being specifically and highly susceptible to ICL inducing agents (Cattell et al., 2010). By 
phenotypically screening a selected set of trypanocidal ABQs against a T. brucei snm1 null 
mutant line, we demonstrated that trypanosomes lacking this DNA repair enzyme were more 
susceptible to NTR and CPR activated prodrugs relative to wild type. Moreover, in parasites 
where TbSNM1 was absent but the activation mechanism (either TbNTR or TbCPR) is 
elevated, this susceptibility phenotype was exacerbated, providing a direct link between the 
two oxidoreductase activities and DNA damage. Extending these assays to investigate the 
trypanocidal action of ABQs that do not undergo NTR or CPR activation, revealed that these 
do not promote a form of DNA damage that can be repaired through an SNM1-dependent 
pathway. It is plausible that these agents may still function as mono- or bi-functional DNA 
alkylating agents, leading to formation of a single site adduct or intrastrand crosslink or could 
act as modifiers of other biological molecules via their aziridinyl or quinone ring structures.  
The continuous in vitro culturing of bloodstream form T. brucei in the presence of RH1 
generated a parasite line that displayed cross-resistance to a range of NTR-activated 
This article is protected by copyright. All rights reserved.
prodrugs. Analysis of clones revealed that these cells had reduced Tbntr expression. 
Additionally, lower mRNA levels were also noted for other open reading frames across the 
~200 kb Tbntr-containing polycistron; however, this effect did not extend to the surrounding 
transcriptional units. In contrast to trypanosomes selected for resistance towards other NTR 
activated prodrugs such as nifurtimox or fexinidazole (Wilkinson et al., 2008, Wyllie et al., 
2016), the copy number of all tested open reading frames in the Tbntr-containing 
transcriptional unit were equivalent to wild type, indicating that the observed reduction in 
gene expression was not due to a large (>10 kb) DNA deletion event; the ‘strandswitch’ 
region, areas on the trypanosomal chromosome postulated to be regions where polycistronic 
transcription is initiated (Imboden et al., 1987, Muhich & Boothroyd, 1988), between the  
Tbntr-containing and adjacent transcriptional units is ~6 kb. Although the exact molecular 
basis that leads to RH1 resistance has yet to be deciphered, it is plausible that the 
transcription initiation site of one of the two Tbntr-containing polycistrons (T. brucei has a 
diploid nuclear genome) may have been compromised resulting in the reduction in mRNA 
levels.  
We have demonstrated that ABQs display significant growth inhibitory activities against 
T. brucei, T. cruzi and L. major, with two compounds (RH1 and TZQ) exhibiting high 
potency (EC50 values <100 nM) against all three pathogens. However, this is accompanied by 
toxicity against macrophage (-like) mammalian cells, a trait previously noted in primary 
mouse splenocytes (Miliukiene et al., 2014). This unwanted activity may be because such 
immune cells have the ability to constitutively express or to up-regulate quinone 
oxidoreductases including NQO1 and NQO1-independent activities that promote oxidative 
stress and/or DNA damage (Tudor et al., 2005, Potts-Kant et al., 2012, Miliukiene et al., 
2014). Although these cytotoxicity issues may preclude the use of these ABQs as therapies 
for the treatment of systemic infections, understanding how they mediate their trypanocidal 
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activities can inform drug development. By exploiting the chemical features that facilitate 
NTR or CPR specific activation such as those reported here, novel trypanocidal prodrugs 
could be generated. Following their activation, these compounds could be designed to release 
cytotoxic metabolites that affect a range of biological processes potentially targeting different 
biochemical pathways. Such agents would be best employed in a polytherapy, as is the case 
with the anti-HAT nifurtimox-eflornithine combination therapy, in order to minimise 
potential resistance. 
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MATERIALS AND METHODS 
Compounds. 
The compounds used in this study were obtained from the following sources: The 
aziridinyl benzoquinones (DZQ, MeDZQ, AZQ, TZQ and ABQ3-4, 6-19, 22-34) (Table 5) 
were supplied by the Drug Synthesis and Chemistry Branch, Developmental Therapeutics 
Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, USA, 
while RH1 was donated by Prof Frank Guziec Jr (Southwestern University, Texas, USA). 
The chemical, physical and potential toxicological properties of each compound can be 
accessed via the PubChem database (http://pubchem.ncbi.nlm.nih.gov/) or OSIRIS Property 
Explorer software (http://www.organic-chemistry.org/prog/). Nifurtimox was obtained from 
Prof Simon Croft (London School of Hygiene and Tropical Medicine, UK), DFMO from Prof 
Mike Barrett (University of Glasgow, UK), mechlorethamine HCl from Stratech Scientific 
Ltd., while puromycin, blasticidin, phleomycin, hygromycin b and tetracycline were 
purchased from Melford Laboratories Ltd.  
 
Cell culturing. 
Bloodstream form T. brucei brucei (MITat 427 strain; clone 221a) cells were cultured in 
HMI-9 media (Life Technologies Ltd) supplemented with 36 mM sodium bicarbonate, 0.014 
% (v/v) β-mercaptoethanol and 10 % (v/v) heat-inactivated foetal calf serum (GE Healthcare) 
as described (Hirumi & Hirumi, 1989). A cell line (2T1) engineered to constitutively express 
the tetracycline repressor protein was grown in the modified HMI-9 medium, supplemented 
with 1 g ml-1 phleomycin (Alsford et al., 2005). T. brucei Tbntr heterozygote lines were 
cultured in the presence of 10 μg ml−1 blasticidin while transformed 2T1 parasites over 
expressing Tbntr, Tbcpr2 or Tbcpr3 were maintained in the modified HIM-9 medium 
supplemented with 1 g ml-1 phleomycin, 2.5 g ml-1 hygromycin b and, where appropriate, 
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1 g ml-1 tetracycline to induce protein expression (Hall et al., 2011). T. brucei lines 
expressing altered levels of the DNA repair enzyme TbSNM1 were grown in the presence 1 
g ml-1 phleomycin, 10 μg ml−1 blasticidin and/or 2 μg ml−1 puromycin, as appropriate 
(Sullivan et al., 2015). 
The epimastigote form of T. cruzi was cultured in RPMI-1640 medium (Lonza) 
supplemented with 5 g l-1 trypticase, 5 g l-1  HEPES pH 8.0, 20 mg l-1 haemin, 0.34 g l-1 
sodium glutamate, 0.22 g l-1 sodium pyruvate, 2500 U l-1 penicillin, 0.25 g l-1 streptomycin 
(all Sigma-Aldrich) and 10 % (v/v) heat-inactivated foetal calf serum (GE Healthcare) at 25 
°C (Kendall et al., 1990). 
The promastigote form of L. major MHOM/IL/80/Friedlin was cultured at 25 °C in 
modified M199 medium (Invitrogen) supplemented with 4 mM sodium bicarbonate, 40 mM 
HEPES pH 7.4, 0.1 mM adenine, 0.005 % (w/v) haemin (all Sigma-Aldrich), 25000 U l-1 
penicillin, 25 mg l-1 streptomycin (GE Healthcare) and 10 % (v/v) heat-inactivated foetal 
bovine serum (GE Healthcare) (Kapler et al., 1990). 
The human acute monocytic leukemia (THP-1) cell line was grown at 37 oC under a 5 % 
(v/v) CO2 atmosphere in RPMI-1640 medium (Lonza) supplemented with 2 mM pyruvate, 2 
mM sodium glutamate, 2.5 U ml-1 penicillin and 2.5 g ml-1 streptomycin, 20 mM HEPES pH 
7.4 and 10% (v/v) heat-inactivated foetal calf serum (GE Healthcare). Differentiation of 
THP-1 toward macrophage-like cells was carried out using 20 ng ml-1 phorbol 12-myristate 
13-acetate (Sigma-Aldrich) (Rovera et al., 1979). 
 
Selective screening of the T. brucei RNAi library. 
Selection of the T. brucei RNAi library was performed as described (Glover et al., 2015).  
Parasites (5 × 106 cells) were treated for 24 hours with 1 g ml-1 tetracycline to induce RNAi 
prior to addition of 30 nM RH1. Periodically the cell density of the culture was determined 
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and when appropriate, diluted in growth medium containing fresh RH1 (30 nM) and 
tetracycline (1 µg ml-1). Once an outgrowth population had been selected, genomic DNA was 
prepared for RNAi target identification (Alsford et al., 2012). 
 
Selection of laboratory generated RH1-resistant T. brucei. 
Wild type bloodstream form T. brucei seeded at 1 x 104 cells ml-1, were cultured in the 
presence of sub-lethal concentration of RH1 (5 nM). Over a 100 day period, the ABQ 
concentration in the culture media was increased in a stepwise manner reaching a final 
concentration of 40 nM. The resulting line (designated as RH1R) was cloned by limiting 
dilution in the presence of RH1 and the phenotype of two clones (RH1RC1 and RH1RC2) 
analysed.  
 
Parasite growth inhibition assays. 
All growth inhibition assays were carried out in a 96-well plate format (ThermoScientific). 
Bloodstream form T. brucei, L. major promastigotes and T. cruzi epimastigotes parasites in 
the logarithmic phase of growth were seeded at 1 x 104, 5 x 105 and 5 x 105 cells ml-1 
respectively in 200 l growth medium containing different concentrations of the compound 
under study. After incubation at 37 °C for 3 days (T. brucei), 25 °C for 6 days (L. major) or  
25 °C for 14 days (T. cruzi), resazurin (Sigma Aldrich) was added to each well at a final 
concentration of 12.5 g ml-1 (or 2.5 g per well). The plates were further incubated at 37 °C 
for 8 hours (T. brucei), 25 °C for 24 hours (L. major) or 25 °C for 24-48 hours (T. cruzi) 
before measuring the fluorescence of each culture using a Gemini Fluorescent Plate reader 
(Molecular Devices) set at λEX =530 nm and λEM =585 nm with a filter cut off at 550 nm. The 
change in fluorescence resulting from the reduction of resazurin is proportional to the number 
of live cells. A compound’s EC50 value was established using the non-linear regression tool 
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on GraphPad Prism (GraphPad Software Inc.) and the statistical significance of any 
differences in parasite susceptibilities assessed using the Student's t test calculator (GraphPad 
Software Inc.). 
 
Mammalian inhibition assays. 
 Differentiated THP-1 cells seeded at 2.5 x 104 cells ml-1 were incubated for 3 days at 37 
°C in a 5 % (v/v) CO2 atmosphere in 200 μl modified RMPI-1640 growth medium containing 
various concentrations of the compound under study. Resazurin (2.5 g per well) was added 
to each culture and the plates incubated for a further 8 hours before determining the 
fluorescence of each sample. 
Experiments involving animals were approved by the Animal Welfare and Ethics Review 
Board at LSHTM and conducted under license in accordance with the Animals (Scientific 
Procedures) Act 1986 (UK Home Office Project Licence PPL70/6997). Peritoneal 
macrophages were isolated from BALB/c mice by lavage 24 hours after intraperitoneal 
injection of 2 % (w/v) soluble starch (Sigma). Macrophages (4 x 105) in RPMI-1640 medium 
(Lonza) supplemented with 10% (v/v) heat-inactivated foetal calf serum (GE Healthcare) 
were adhered overnight at 37 °C in a 5 % (v/v) CO2 atmosphere onto a 16-well chamber 
slide. Cells were then treated with various concentrations of the compound under study and 
the cultures incubated at 37 °C up to 5 days under a 5 % (v/v) CO2 atmosphere. Untreated 
controls were analysed in parallel on each slide. Macrophages were fixed in 100% (v/v) 
methanol, stained with 10 % (w/v) Giemsa, visualized with Leica DMRA2 light microscope 
using a x100 oil immersion objective and images captured using a Retiga EXi Fast 1394 
digital camera.  The number of cells per field of view was determined with a minimum of 10 
fields examined for each drug treatment. The average number of cells per field of view was 
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determined and expressed as a % relative to untreated controls. All treatments were 
performed in quadruplicate.  
 
Quantitative PCR (qPCR). 
The copy number and mRNA levels of various genes were analysed by qPCR. Genomic 
DNA or total RNA was prepared from wild type or RH1-resistant T. brucei using the DNeasy 
Blood and Tissue or RNeasy Extraction kits (Qiagen), respectively. cDNA was synthesized 
from total RNA using the Superscript VILO cDNA synthesis kit (Invitrogen). All qPCRs 
were performed in triplicate with the PerfeCTa qPCR FastMix kit (Quanta Biosciences) on a 
CFX96 Touch Real-Time PCR Detection System (BioRad). Fluorescence data was collected 
using the CFX Manager Software (BioRad), the products analysed by a melt curve after the 
final cycle and normalized against telomerase reverse transcriptase (Tbtert; Tb11.01.10190) 
using the comparative CT method (Schmittgen & Livak, 2008, Brenndorfer & Boshart, 2010). 
 
Cell cycle arrest assay 
Wild type T. brucei (5 x 105 ml-1) were cultured for 16 hours in the presence of mutagen (1 
µg ml-1 phelomycin; 35 µM mechlorethamine; 100 nM RH1). Cells were washed in 
phosphate buffered saline (PBS), fixed in 2% (w/v) paraformaldehyde in PBS and washed 
once more in PBS. Aliquots of the cell suspension (~105 cells) were air-dried onto 
microscope slides and the samples mounted in Vectashield containing 4, 6-diamidino-2-
phenylindole (Vector Laboratories Ltd). Images were captured using Leica DMRA2 epi-
fluorescent microscope fitted with a digital camera (Hamamatsu Photonics).  
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TABLES 
Table 1: Potency of aziridinyl benzoquinones. Data represents the EC50 values of various ABQs towards bloodstream form T. brucei, T. cruzi 
epimastigotes, L. major promastigotes and differentiated THP-1 cells. All values are means ± standard deviation of four (parasites) or three 
(mammalian cells) independent experiments. aActivity of DZQ, MeDZQ, RH1, TZQ and ABQ’s 6-9, 14, 15, 20, 22 against T. brucei was 
previously reported (Hall et al., 2012). bDifferentiated THP-1 EC50 value towards nifurtimox taken from (Voak et al., 2013). The Selectivity 
Index (SI) of certain compounds (fold difference in EC50 values of the THP-1 line relative to parasite) is noted. CABQ3 was unstable with its 
potency diminishing following repeated freeze/thawing. 
 












2700 ± 100 >37 2600 ± 400 >38 6280 ± 40  >16 >100000 
ABQ7, 9-12, 16-19, 
28, 31, 32, 34 
 
>10000 - >10000  >10000  - 
DZQ 272 ± 1 1 5 ± 1 36 60 ± 1 3 181 ± 5 
MeDZQ 698 ± 57 1 55 ± 2 16 560 ± 139 2 885 ± 23 
ABQ3c 400 ± 30 - 6200 ± 1160 - 199 ± 4 - - 
ABQ4  1180 ± 160 - 106 ± 25 - 663 ± 6 - - 
RH1 19 ± 1  <5 3 ± 1 <33 68 ± 1 <1 <100 
ABQ6 283 ± 41  2 205 ± 53 5 664 ± 2 2 1067 ± 159 
ABQ8  670 ± 30  4 1300 ± 108 2 1870 ± 184 2 2951±  770 
ABQ13  >10000 - 5550 ± 240 - >10000 - - 
ABQ14 >10000 - 445 ± 30 - 2270 ± 17 - - 
ABQ15 >10000 - 3310 ± 200 - >10000 - - 
AZQ 8233 ± 272 - 6000 ± 283 - >10000 - - 
TZQ 179 ± 1 <1 3 ± 1 <33 9 ± 1 <11 <100 
ABQ22 148 ± 1 1 55 ± 2 3 218 ± 20 1 138 ± 25 
ABQ23 2300 ± 60 <1 2180 ± 670 <1 348 ± 166 1 <400 
ABQ24 1470 ± 120 <1 37  ± 1 <11 473 ± 123 <1 <400 
ABQ25 >10000 - - - 80 ± 6  - - 
ABQ26 >10000 - 8638 ± 736  - 2360 ± 230  - - 
ABQ27 >10000 - 620 ± 180  - 210 ± 10  - - 
ABQ29 - - 975 ± 25  - 175 ± 5  - - 
ABQ30 7400 ± 190 <1 980 ± 25 4 174 ± 10 22 3750 ± 320 
ABQ33 >10000 - >10000 - 8157 ± 80  - - 
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Table 2: Growth inhibitory effect of ABQs towards T. brucei expressing elevated levels 1 
of potential activators. Data represents the EC50 values of parasites expressing wild type 2 
(control), elevated levels of TbNTR (Tbntr++) or TbCPR2 (Tbcpr2++). All values are means ± 3 
standard deviation of four independent experiments. The fold difference in EC50 values of the 4 
over expressing lines relative to control is given in parentheses. Parasites over expressing 5 
TbCPR3 behaved similarly to those expressing elevated levels of TbCPR2. atrypanocidal 6 
activity of DZQ MeDZQ, RH1, ABQ6, TZQ and ABQ22 towards T. brucei cells over 7 
expressing Tbntr was previously reported (Hall et al., 2012). *The difference in susceptibility 8 
of wild type and Tbntr++ lines to nifurtimox, DZQ, MeDZQ, RH1 and TZQ was statistically 9 
significant (P < 0.01), as assessed by Student's t test. **The difference in susceptibility of 10 
wild type and Tbcpr++ lines to ABQ22 was statistically significant (P < 0.01), as assessed by 11 
Student's t test.  12 












DFMO 27500 ± 108 30720 ± 1330 (1.12) 33250 ± 5123 (1.21) 
Nifurtimox 
 
2980 ± 30 315 ± 15 (0.11*) - 
DZQ 318  ± 38 90 ± 3 (0.28*) - 
MeDZQ 740 ± 18 115 ± 3 (0.16*) - 
RH1 19 ± 1 3 ± 1 (0.16*) 20 ± 3 (1.05) 
TZQ 225 ± 26 60 ± 9 (0.27*) 284 ± 13 (1.26) 
ABQ22 138 ± 25 148 ± 9 (1.07) 20 ± 3 (0.14**) 
ABQ23 2935 ± 420 3315 ± 540  (1.13) 3556 ± 96 (1.21) 
ABQ24 1470 ± 120 2090 ± 160 (1.42) 1698 ± 23 (1.16) 
ABQ30 7400 ± 190 8670 ± 1670 (1.12) - 
 14 
15 
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Table 3: Susceptibility of RH1 resistant T. brucei to trypanocidal agents. Data represent 16 
the growth-inhibitory effect as judged by their EC50 values of various agents on BSF T. 17 
brucei wild type and RH1RC1 cells. All values are means ± standard deviation from 18 
independent experiments preformed in quadruplicate. The ratio represent the fold difference 19 
in EC50 value between the RH1RC1 and wild type lines to a given compound. #identifies 20 
TbNTR-activated prodrugs. * indicates significant differences in susceptibility (P < 0.001) 21 
between wild type and RH1RC1 lines, as assessed by Student's t test (GraphPad Software Inc.). 22 
 23 
Compound 




Aziridines     
  Triethylenemelamine   2400 ± 86 2774 ± 64 1.1 
  ThioTEPA 39423 ± 796 56298 ± 1960 1.4 
  RH1# 25 ± 6 83 ± 2* 3.3 
  ABQ22 197 ± 31 232 ± 27 1.2 
  CB1954# 2161 ± 125 13086 ± 972* 6.5 
     
Nitrogen mustards    
  Mechlorethamine   32063 ± 1021 27203 ± 1288 0.8 
  Melphalan  8740 ± 200 10430 ± 230 1.2 
  LH17# 5438 ± 444 17998 ± 1106* 3.6 
     
Nitrosoureas    
  Lomustine 16650 ± 443 15463 ± 665 0.9 
  Semustine   15025 ± 3457 17100 ± 3619 1.1 
     
Other agents    
  DFMO  16763 ± 2691 22177 ± 383 1.3 
  Nifurtimox#  2700 ± 100 7050 ± 311* 2.6 
  Megazol# 166 ± 1 454 ± 4* 2.7 
  24 
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Table 4: Susceptibility of T. brucei Tbsnm1 null mutants to ABQ compounds. Data 25 
represents the EC50 values of selected ABQ compounds towards wild type T. brucei (control) 26 
and T. brucei Tbsnm1 null mutants (ΔTbsnm1). All values are means ± standard deviation of 27 
four independent experiments. The ration of EC50 values between the two parasite lines are 28 
given. *indicates significant differences in susceptibility (P < 0.01) between the wild type 29 
and ΔTbsnm1 lines, as assessed by Student's t test (GraphPad Software Inc.). 30 





Nifurtimox 2850 ± 20 2250 ± 090 0.79 
DFMO 27500 ± 108 27100 ± 850 0.99 
DZQ 157 ± 23 43 ± 2* 0.27 
RH1 19 ± 1 5 ± 1* 0.26 
TZQ 253 ± 33 46 ± 1* 0.18 
ABQ22 138 ± 25 21 ± 5* 0.15 
ABQ23 2300 ± 60 2410 ± 160 1.01 
ABQ24 1470 ± 120 1130 ± 100 0.77 
  32 
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Table 5. Structure of aziridinyl 1,4-benzoquinones used in this study. All compounds tested satisfy Lipinski’s Rule of 5 33 
(http://pubchem.ncbi.nlm.nih.gov/) although all are predicted to have toxicity risks (http://www.organic-chemistry.org/prog/peo). 34 
 35 
 
Compound Structure  Compound Structure 
ABQ1 (DZQ) R1=R2=X=Y=H  ABQ18 R1=R2=NHCO(CH2)5CH3; X=Y=H 
ABQ2 (MeDZQ) R1=R2=CH3; X=Y=H  ABQ19 R1=R2=NHCOPhenyl; X=Y=H 
ABQ3 R1=R2=Br; X=Y=H  ABQ20 (AZQ) R1=R2=NHC(O)OCH2CH3; X=Y=H 
ABQ4 R1=R2=F; X=Y=H  ABQ21 (TZQ) R1=azirindyl; R2=X=Y=H 
ABQ5 (RH1) R1=CH2OH; R2=CH3; X=Y=H  ABQ22 R1=R2=azirindyl; X=Y=H 
ABQ6 R1=R2=OCH3; X=Y=H  ABQ23 R1=R2=X=H;Y=CH3 (r orientation) 
ABQ7 R1=R2=OCH2CH3; X=Y=H  ABQ24 R1=R2=X=H;Y=CH3 (s orientation) 
ABQ8 R1=R2=O(CH2)2CH3; X=Y=H  ABQ25 R1=R2=Br; X=H; Y=CH3 
ABQ9 R1=R2=NH2; X=Y=H  ABQ26 R1=R2=Br; X=Y=CH3 
ABQ10 R1=R2=NHCH3; X=Y=H  ABQ27 R1=R2=Cl; X=H;Y=CH3 
ABQ11 R1=R2=NHCH2CH3; X=Y=H  ABQ28  R1=R2=Cl; X=Y=CH3 
ABQ12 R1=R2=NH(CH2)6CH3; X=Y=H  ABQ29 R1=R2=F; X=H;Y=CH3 
ABQ13 R1=R2=NH(CH3)CH3; X=Y=H  ABQ30 R1=R2=F; X=Y=CH3 
ABQ14 R1=morpholinyl; R2=F; X=Y=H  ABQ31 R1=R2=NHCOCH3; X=H; Y=CH3 
ABQ15 R1=R2=NHCOCH3; X=Y=H  ABQ32 R1=R2=NHCOCH3; X=Y=CH3 
ABQ16 R1=R2=NHCOCH2CH3; X=Y=H  ABQ33 R1=R2=NHCOCH2CH3; X=H;Y=CH3 
ABQ17 R1=R2=NHCO(CH2)2CH3; X=Y=H  ABQ34 R1=R2=NHCOOCH2CH3; X=Y=CH3 
 36 
  37 
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FIGURE LEGENDS 
Fig. 1. Screening for RH1 resistant determinants using a genome-scale T. brucei RNAi 
library. A. The bloodstream form T. brucei RNAi library (Alsford et al., 2012) was co-
treated with RH1 (30 nM) and tetracycline (1 µg ml-1), the latter to induce RNAi, with the 
cumulative cell growth of the culture followed. The arrows correspond to culture dilution and 
addition of fresh RH1 (30 nM) and tetracycline (1 µg ml-1). Genomic DNA (as indicated by 
stars) was extracted from parasites at days 9 and 12. Insert shows structure of RH1. B. 
Amplification of the RNAi target from the RH1 screen using genomic DNA extracted on day 
9 of selection and the LIB2f (TAGCCCCTCGAGGGCCAGT) and LIB2r 
(GGAATTCGATATCAAGCTTGGC) primers (lane 1) produced a major fragment mapping 
to the type I nitroreductase (Tbntr) locus (gene id Tb927.7.7230 on the TriTrypDB; 
http://tritrypdb.org/tritrypdb/). M indicates a size marker in bp. C. Genetic map (black boxes 
represent protein-coding sequences) of the Tbntr locus, indicating the location of the major 
RNAi target fragment (grey box) recovered from the library following RH1-selection. 
 
Fig. 2: Susceptibility of T. brucei expressing altered levels of activator to RH1 or 
ABQ22. A. Dose response curve of wild type (solid line) and Tbntr heterozygous (dotted 
line) T. brucei to RH1. The extrapolated EC50 values (in nM) of wild type (white bar) and 
Tbntr heterozygous (grey bar) T. brucei to RH1 are shown. B. Dose response curve of wild 
type (solid line) and TbNTR overexpressing (dotted line) T. brucei to RH1. The EC50 values 
(in nM) of wild type (white bar) and TbNTR overexpressing (grey bar) T. brucei to RH1 are 
shown. C. Dose response curve of wild type (solid line) and TbCPR2 overexpressing (dotted 
line) T. brucei to ABQ22. The extrapolated EC50 values (in nM) of wild type (white bar) and 
TbCPR2 overexpressing (grey bar) T. brucei to RH1 are shown. All data are means for 
experiments performed in quadruplicate ± standard deviation. *indicates significant 
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differences in susceptibility (P <0.01) between wild type and genetically modified cells to 
RH1, as assessed by Student's t test (GraphPad Software Inc.). 
 
Fig. 3: RH1 resistance selection in T. brucei. A. Selection of RH1 resistant T. brucei was 
performed by the stepwise increase of the ABQ (black line). The cumulative cell density of 
three independent cultures (grey lines) were monitored throughout the selection with only one 
of these (RH1R) generating an outgrowth in medium containing >20 nM RH1. Clones from 
the RH1R culture were then generated following limiting dilution. B. Cumulative cell density 
of wild type T. brucei (black lines) and a clone (RH1RC1) derived from RH1R (grey lines) 
grown in medium lacking (solid lines) or containing 40 nM RH1 (dashed lines). Data points 
are averages ± standard deviation from experiments performed in quadruplicate. A second 
RH1R derived clone (RH1RC2) analysed in parallel displayed similar growth properties (data 
not shown). C. Dose response curves of wild type T. brucei (black solid line), RH1RC1 (black 
dashed line) and RH1RC2 (grey solid line) to RH1. All data points are averages from 
experiments performed in quadruplicate ± standard deviation. D. Susceptibility of T. brucei 
to RH1 as judged by the EC50 values (in nM). *indicates significant differences in 
susceptibility (P <0.001) between wild type and genetically modified cells to RH1, as 
assessed by Student's t test (GraphPad Software Inc.). 
 
Fig. 4: Evaluating the mechanism underlying RH1 resistance in T. brucei. A. Schematic 
of T. brucei chromosome 7 that contains Tbntr. This gene is part of a 200 kbp polycistronic 
region (see Expanded view) that encodes for ~60 open reading frames (ORF) (light grey 
arrowed box) and is approx. 75 kbp downstream from a ‘strandswitch’ region, areas on the 
trypanosomal chromosome that are postulated to be regions where polycistronic transcription 
is initiated (Imboden et al., 1987, Muhich & Boothroyd, 1988). The position of selected 
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ORFs from the Tbntr-containing polycistronic transcriptional unit plus the telomeric repeats 
(black arrow repeats) are shown. Other selected polycistrons on chromosome 7 are also 
highlighted (dark grey arrowed boxes). B and C. The mRNA levels (panel B) and gene copy 
number (panel C) of selected ORFs located on chromosome 7 from wild type (grey bar) and 
RH1RC1 (white bar) cells was evaluated by qPCR. This was compared against the expression 
level/gene copy number of a standardized control (Tbtert) and the average fold difference, as 
judged by 2-(ΔΔCT) from reactions performed in triplicate ± standard deviation, plotted as a 
measure of the relative expression level. * and ** indicates significant differences in relative 
mRNA expression levels (P <0.01 and  <0.02, respectively) between the wild type and 
RH1RC1, as assessed by Student's t test (GraphPad Software Inc.). 
 
Fig. 5: RH1 promotes cell cycle arrest in T. brucei. A. The effect of ICL inducing agents 
(mechlorethamine (HN2) or RH1) on the trypanosome cell cycle was analysed by 
determining the relative number of nuclear (N) and mitochondrial (K) genomes structures 
within a single parasite. T. brucei in the G1/S phase have a 1N1K arrangement (black bar), 
those in G2/M phase possess a 1N2K ratio (grey bar) while cells displaying a 2N2K profile 
are in the post-M stage (hatched bar) (Woodward & Gull, 1990, Siegel et al., 2008, Glover 
and Horn, 2012). The number of cells (n) analysed for each treatment (untreated, phleomycin 
treated, mechlorethamine (HN2) or RH1) is given.  
 
Fig. 6: Susceptibility of T. brucei lines expressing altered levels of TbSNM1 to selected 
azirindinyl benzoquinones. Growth inhibitory effects, as judged by EC50 values, of RH1, 
TZQ and ABQ22 (all in nM) in the T. brucei wild type, Tbsnm1 null mutant (ΔTbsnm1) and 
Tbsnm1 null mutants expressing an ectopic copy of Tbsnm1 (ΔTbsnm1 Tbsnm1++) lines 
(Sullivan et al., 2015). DFMO (in µM) was used as a non-DNA damaging agent control. Data 
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are mean values ± standard deviations from experiments performed in quadruplicate. 
*indicates significant differences in susceptibility (P <0.001) between wild type and 
ΔTbsnm1 or between ΔTbsnm1 and ΔTbsnm1 Tbsnm1++ cells to RH1, as assessed by 
Student's t test (GraphPad Software Inc.). 
 
Fig. 7: Linking aziridinyl benzoquinone prodrug activation to DNA damage. A. Growth 
inhibitory effects, as judged by EC50 values, of RH1, TZQ, ABQ22 (all in nM) and DFMO 
(in µM) in the T. brucei wild type, T. brucei expressing an ectopic copy of Tbntr (Tbntr++), 
Tbsnm1 null mutant (ΔTbsnm1) and Tbsnm1 null mutants expressing elevated levels of Tbntr 
(ΔTbsnm1 Tbntr++) lines. * and ** indicates significant differences in susceptibility (P 
<0.001 and <0.03, respectively) between the ΔTbsnm1 Tbntr++ line relative to the Tbntr++ or 
ΔTbsnm1 parasites to RH1 and TZQ, as assessed by Student's t test (GraphPad Software 
Inc.). B. Growth inhibitory effects, as judged by EC50 values, of RH1, TZQ and ABQ22 (all 
in nM) in the T. brucei wild type, T. brucei expressing an ectopic copy of Tbcpr2 (Tbcpr2++), 
Tbsnm1 null mutant (ΔTbsnm1) and Tbsnm1 null mutants expressing elevated levels of 
Tbcpr2 (ΔTbsnm1 Tbcpr2++) lines: the latter lines was validated as previous described (Hall 
et al., 2011, Sullivan et al., 2015). DMFO (in µM) was used as a non-DNA damaging agent 
control. * and ** indicates significant differences in susceptibility (P = 0.01 and P < 0.003, 
respectively) between the ΔTbsnm1 Tbcpr2++ line relative to the Tbcpr2++ or ΔTbsnm1 
parasites to ABQ22, as assessed by Student's t test (GraphPad Software Inc.). Data in panels 
A and B are mean values ± standard deviations from experiments performed in quadruplicate. 
 
Fig. 8: Proposed mechanism of action and trypanocidal structure activity relationships 
of ICL-forming ABQs. A. Quinones can be reduced to hydroquinones by two distinct 
pathways. In one pathway, enzymes such as cytochrome P450 reductase (CPR) mediate the 
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1e- reduction of the quinone to a semiquinone radical. This then undergoes further reduction 
to the hydroquinone. In the presence of O2, the semiquinone can undergo futile cycling to 
form O2.- & the parental quinone. In the other system, reduction of the quinone to the 
hydroquinone occurs directly via a 2e- reduction event as typified by a type I nitroreductase 
(NTR) activity. Formation of the hydroquinone then facilitates protonation of the nitrogen 
atoms in the aziridine rings with these electrophilic intermediates undergoing nucleophilic 
attack (e.g. by DNA), promoting opening of the aziridinyls, formation of aliphatic amine 
intermediates and alkylation of the target. As ABQs contain two (or more) aziridinyls they 
can covalently bind the two complementary DNA strands together resulting in an interstrand 
crosslink. B. ABQs (e.g. DZQ, MeDZQ, RH1 and TZQ) possessing small (e.g. hydrogen, 
methyl, hydroxymethyl) substituent groups (small solid spheres) at the 3,6 positions on a 
benzoquinone core are more likely to be activated in T. brucei by the type I nitroreductase 
(NTR) but not by cytochrome P450 reductase (CPR) (i). ABQs that contain methyl 
substituted (small solid spheres) aziridines (e.g. ABQ23, 24 and 30) are not activated in T. 
brucei by NTR or CPR (ii). ABQ22, a compound that contains aziridinyl rings at the 3,6 
positions on the benzoquinone core, is readily activated within the trypanosome by CPR but 
not by NTR (iii). ABQs (e.g. ABQ9-19) having bulky substituent groups (large ssolid pheres) 
at the 3,6 positions on the benzoquinone ring generally display no significant trypanocidal 
activity (iv). 
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Trypanocidal mechanism of aziridinyl benzoquinones. Reduction of quinones to 
hydroquinones occurs: indirectly by a series of 1e
-
 reductions (e.g. by cytochrome P450 
reductases (CPR)), or directly by a 2e
-
 reduction (e.g. by type I nitroreductases (NTR)). 
Hydroquinone formation facilitates aziridine protonation, promoting nucleophilic attack e.g. 
by DNA, and leads to alkylation of the target. As the aziridinyl benzoquinones tested here 
contain multiple aziridinyls, they can bind to the complementary DNA strands generating 
interstrand crosslinks. 
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